
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Click the title above to open the Pharmaceutical Executive February 2020 issue in an interactive PDF format.
almost 7 years ago
Improving the Link from Lab to Physicianalmost 7 years ago
Engaging the New HCP in the Digital Worldalmost 7 years ago
Jay Galeota: A Better Way to Pharmaalmost 7 years ago
Surfacing Insights: AI and the Physicianalmost 7 years ago
Becoming a Pharma Industry Leaderalmost 7 years ago
Unlocking the Black Box of Pharma Pricing in Europealmost 7 years ago
The Risks and Rewards of Expedited Reviewalmost 7 years ago
Using Service to Drive Commercial Valuealmost 7 years ago
The Roots and Rise of Cell and Gene Therapyalmost 7 years ago
Pharma Outsourcing: Keys to Productivity in 2020s




